/

Aclaris Therapeutics, Inc.

ACRS US

ACRS USAclaris Therapeutics, Inc.

United States Composite

1.20

USD

+0.01

(+0.84%)

-1.27EPS Dil.

-0.95P/E

85.07MMarket Cap

Aclaris Therapeutics, Inc.

ACRS

(United States Composite)

Recent

price

1.20

P/E

ratio

-0.95

div

yld

- -

ROIC.AI

Legends:

Stock price

0.02

Beta (1.0 Market)

% total return 04/29

Stock

S&P500

YTD

-86.28

- -

-95.11

- -

-82.11

- -

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

- -

0.06

0.19

0.10

0.15

0.12

0.46

0.45

- -

-0.65

-0.99

-3.79

-2.25

-2.44

-4.03

-3.90

-1.20

-1.60

-1.33

-1.27

- -

-0.46

-0.76

-3.42

-1.63

-1.99

-3.10

-2.37

-0.92

-1.05

-1.14

- -

-0.86

-1.95

-2.12

-3.49

-5.17

-7.09

-10.93

-11.18

-9.72

-10.23

-10.87

- -

-0.86

-1.95

4.59

6.50

6.46

4.59

1.51

0.68

3.11

2.86

2.21

- -

-3,170.59

-1,378.31

-2,172.23

-748.52

-967.08

-286.21

-372.22

- -

-5

-9

-21

-48

-69

-133

-161

-51

-91

-87

-88

- -

-4,071.48

-2,157.99

-3,817.22

-787.03

-1,343.96

-292.11

-283.15

- -

132

187

152

182

210

- -

-9

-21

169

225

215

197

198

157

- -

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

- -

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

734

485

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

133

123

129

Cash, Cash Equivalents & STI

120

103

119

Accounts Receivable, Net

Inventories

- -

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

73.05%

3.33%

Net Income, GAAP

-50.63%

-5.58%

-1.15%

Free Cash Flow

-44.89%

-3.52%

-17.65%

Total Cash Common Dividend

- -

Total Equity

-28.07%

57.01%

-20.71%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.57

-0.34

-0.35

-0.37

-1.60

2022

-0.31

-0.30

-0.41

-1.33

2023

-0.42

-0.41

-0.02

-1.27

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Business: Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Company News

Zacks
24 days ago
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Zacks
a month ago
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

- -

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

- -

0.06

0.19

0.10

0.15

0.12

0.46

0.45

- -

-0.65

-0.99

-3.79

-2.25

-2.44

-4.03

-3.90

-1.20

-1.60

-1.33

-1.27

- -

-0.46

-0.76

-3.42

-1.63

-1.99

-3.10

-2.37

-0.92

-1.05

-1.14

- -

-0.86

-1.95

-2.12

-3.49

-5.17

-7.09

-10.93

-11.18

-9.72

-10.23

-10.87

- -

-0.86

-1.95

4.59

6.50

6.46

4.59

1.51

0.68

3.11

2.86

2.21

- -

-3,170.59

-1,378.31

-2,172.23

-748.52

-967.08

-286.21

-372.22

- -

-5

-9

-21

-48

-69

-133

-161

-51

-91

-87

-88

- -

-4,071.48

-2,157.99

-3,817.22

-787.03

-1,343.96

-292.11

-283.15

- -

132

187

152

182

210

- -

-9

-21

169

225

215

197

198

157

- -